News | January 06, 2014

Studies Assessing Stentys in Indications Outside of Heart Attacks Presented at TCT 2013

stentys self-apposing stent clinical trial study TCT 2013 cath lab

January 6, 2014 — Stentys, developer of the world's first self-apposing stent to treat acute myocardial infarction (AMI), announced new data in indications outside of myocardial infarction. Results from the OPEN II study and a series from the Amsterdam Medical Center were presented during the TCT conference (TCT 2013) in San Francisco.
 
OPEN II is a prospective, single-arm trial that enrolled 217 patients treated for chest pain due to a narrowing at a coronary artery bifurcation with the Stentys paclitaxel-eluting stent in 21 hospitals in six European countries. The primary endpoint of MACE (composite of cardiac death, myocardial infarction, emergent bypass surgery and target lesion revascularization) at six months was 10.1 percent for the whole study group, with a rate of 6.9 percent in patients with simple lesions. Christoph Naber, M.D., Ph.D., Contilia Heart and Vascular Center, Essen, Germany, and principal investigator of the study, presented the results.
 
“This large study in a highly complex group of patients with challenging lesions confirms that the Stentys stent can be used in routine practice and leads to very good results compared to those published historically,” said Naber.
 
Huangling Lu, M.D., from Amsterdam Medical Center, Netherlands, also presented a series of 87 patients treated with Stentys at her institution. This series enrolled primarily patients with atypical anatomy: 53 percent had aneurysmatic or ectactic vessels, 31 percent had tapered vessels, 23 percent had large vessels (above 4.5 mm) and 10 percent had bypass grafts. At 12 months, the MACE rate was 4.7 percent.
 
“The Self-Apposing stent is the only available product that can conform to complex, non-cylindrical vessel anatomy, as detailed on its recently extended CE mark label,” said Gonzague Issenmann, CEO and co-founder, Stentys.
 
The Stentys Self-Apposing stent is engineered to solve the dilemma of artery diameter discrepancy. Its flexible, self-expanding design takes the shape of the patient’s unique vessel anatomy and apposes to the irregular contours of a blood vessel.
 
For more information: www.stentys.com

Related Content

News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — People with a small aortic annulus, a part of the heart’s anatomy where the left ventricle meets the ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 8, 2024 — People with diabetes who had suffered a heart attack derived no clinical benefit from edetate disodium ...

Home April 08, 2024
Home
Subscribe Now